comparative effectiveness

Videos

Definitive vs Conservative Treatments for Older Men With Prostate Cancer

02/24/2021

Journal of Clinical Pathways

Videos

Enzalutamide vs Apalutamide, Darolutamide, and Bicalutamide for Nonmetastatic CRPC

02/23/2021

Journal of Clinical Pathways

Conference Coverage

Weekly vs Biweekly Cetuximab for Metastatic Colorectal Cancer

01/19/2021

Journal of Clinical Pathways

News

Comparison of Costs, Outcomes Among Neoadjuvant-Adjuvant Treatment Strategies for Breast Cancer

12/08/2020

Journal of Clinical Pathways

Conference Coverage

Watch and Wait vs Initial Treatment for Advanced FL

12/03/2020

Journal of Clinical Pathways

News

Effective, Less Toxic Treatment Option Identified for Aggressive B-Cell Lymphoma

05/29/2020

Risk-adapted dose-adjusted etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, and rituximab (DA-EPOCH-R) therapy is effective and well tolerated in adults with Burkitt lymphoma regardless of age or...

...

05/29/2020

Journal of Clinical Pathways

News

Real-World HRU, Costs in Patients With MCL Treated With Drug Combo vs Chemoimmunotherapy

05/20/2020

Researchers recently compared health care resource utilization (HRU) and costs of relapsed or refractory (R/R) mantle cell lymphoma (MCL) patients treated with ibrutinib ± rituximab (I±R) or chemoimmunotherapy (CIT)...

...

05/20/2020

Journal of Clinical Pathways

News

High Risk of Preventable and Mitigable Adverse Events in Cancer Care

08/22/2017

JCP Editors

Researchers have identified a significant burden of adverse events across the cancer care continuum, including preventable or mitigable events, according to a study published in Cancer (online August 17, 2017;...

...

08/22/2017

Journal of Clinical Pathways

Research in Review

Resistance Mutations Predict Metastatic Patterns in NSCLC

08/17/2017

JCP Editors

Specific gene rearrangements associated with increased resistance to standard therapy may predict different metastasis distributions in patients with non-small cell lung cancer (NSCLC), according to research...

...

08/17/2017

Journal of Clinical Pathways

Author Insights

Cost-Effective Alternative Identified for Autologous Stem Cell Mobilization in Multiple Myeloma

08/14/2017

Pavan Bhamidipati, MBBS, MD

In a randomized, open-label study, we discovered that tbo-filgrastim (Granix) can be used in the place of filgrastim (Neupogen) for autologous stem cell mobilization for multiple myeloma and non-Hodgkin’s lymphoma...

In a...

08/14/2017

Journal of Clinical Pathways